November 6, 2023 11:31 AM EST
News Briefing

Zen­tal­is shakes up PhI­II plans in ovar­i­an can­cer; Halozyme's deal with Acu­men; Ko­r­ro's $117M pri­vate place­ment

Lei Lei Wu

News Reporter

Jaimy Lee

Deputy Editor

Zen­tal­is Phar­ma shakes up plans for Phase III in ovar­i­an can­cer: Zen­tal­is an­nounced Mon­day that it is no longer plan­ning to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times